Standard BioTools posts $20.1 million in Q2 revenue, adjusted EBITDA loss narrows 84%

GlobeNewswire··US·Read original
2▲0 ▼1Impact / 5
Summary · why it matters

Standard BioTools reported second-quarter 2026 revenue of $20.1 million, a 7.6% decline from the prior year, while its adjusted EBITDA loss improved 84% to $2.5 million. The company said its merger with Treeline Biosciences is progressing toward a stockholder vote and is expected to close before year-end 2026. Operating expenses fell 1% to $35.9 million, though the net loss from continuing operations widened to $21.5 million, partly due to one-time transaction costs. Standard BioTools also withdrew its full-year 2026 revenue outlook because of the pending merger.

Impact on assets 2

Biotech & Genomic Medicine▼ · 2 stocks
Standard Biotools Inc
LAB
▼ NegativeCapitalrelevance

Q2 revenue declined 7.6% and net loss widened due to transaction costs, though EBITDA loss narrowed

Off-coverage companies 1

Treeline BiosciencesPrivate▲ Positive
Capitalrelevance

Merger with Standard BioTools progressing toward stockholder vote and expected to close before year-end

© 2026 MarketIVNews